NEW YORK (GenomeWeb) – Alere on Thursday reported that its second quarter revenues fell 9 percent year over year, driven primarily by sinking sales in its cardiometabolic disease and infectious disease test segments.

For the three months ended June 30, the firm reported revenues of $557.7 million compared to restated revenues of $610.3 million in Q2 2016. The firm said that its financial results for Q2 reflect a $6 million negative impact of foreign currency exchange.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.